Navigation Links
Green tea may negate the effects of a common cancer therapy
Date:2/3/2009

(WASHINGTON, February 3, 2009) Green tea products have become regarded as a valuable health supplement, as studies have shown evidence of its benefit against a variety of diseases, including cancer. However, a new study suggests that some components of green tea may counteract the anticancer effects of one cancer therapy, bortezomib (Velcade), and may be contraindicated for patients taking this medicine to ensure its maximum therapeutic benefit. This study is being prepublished online today in Blood, the official journal of the American Society of Hematology.

Because of its increasing popularity and availability to the public in many formulations, green tea has been increasingly studied to understand its effect on cancer, heart disease, and other conditions. In animal studies, an antioxidant compound in green tea called the EGCG polyphenol (epigallocatechin gallate) has been shown to be a potent anticancer agent, with effects demonstrated against leukemia, as well as lung, prostate, colon, and breast cancer. Among other properties, EGCG binds to a common protein in tumors called GRP78 (which is responsible for preventing cell death) and inhibits its function, thereby assisting in the death of tumor cells.

We know that cancer patients look to green tea extracts among other natural supplements to complement their therapeutic regimens. We wanted to better understand how the compounds in green tea interact with a cytotoxic chemical therapy and how that may affect patient outcomes, said Axel Schnthal, PhD, of the University of Southern California Keck School of Medicine and senior study author.

In this study, researchers evaluated whether the combination of green tea and bortezomib would improve outcomes against multiple myeloma, a blood cancer, and glioblastoma, a malignant brain tumor. Bortezomib, an anticancer therapy approved to treat multiple myeloma and mantle cell lymphoma, normally fights disease by inhibiting proteasomes and inducing tumor cell death. However, in both in vitro and in vivo mouse experiments, the team was surprised to find that the EGCG compound seemed to prevent bortezomib from fighting the disease by blocking its proteasome inhibitory function the two compounds effectively contradicted one another in the cell, leaving nearly 100 percent of the tumor cells intact.

Importantly, the team found that EGCG only reacted with proteasome inhibitors that have a boronic acid base (including bortezomib) but did not react with several non-boronic acid-based proteasome inhibitors (such as nelfinavir [Viracept], a treatment for HIV). The researchers determined that the boronic acid in bortezomib helped to bind the EGCG directly to the therapy molecule, thereby cancelling out the effects of both the green tea and the therapy on the tumor cells.

The study findings may have several important implications in the clinical setting. The EGCG blocked bortezomibs antitumor effects at levels that are commonly achieved with the use of available concentrated green tea supplements (as low as 2.5 μM which can be attained with two to three 250 mg capsules of green tea extract) suggesting the impact is very real for patients supplementing their therapy. The team also believes that as the EGCG inactivates bortezomibs function in the tumor cell, it may also prevent some of the side effects that usually accompany the therapy. As a result, patients taking green tea products to supplement their therapy may experience improved well being and feel encouraged to increase their intake while unknowingly blunting or completely negating the efficacy of their bortezomib treatment.

Our surprising results indicate that green tea polyphenols may have the potential to negate the therapeutic efficacy of bortezomib, said Dr. Schnthal. The current evidence is sufficient enough to strongly urge patients undergoing bortezomib therapy to abstain from consuming green tea products, in particular the widely available, highly concentrated green tea and EGCG products that are sold in liquid or capsule form.

The findings of the study are considered specific for patients taking bortezomib as opposed to any other common cancer therapy. The analysis of the study offered a clear understanding of the boronic acid-related mechanisms that cause the negative outcome, offering the conclusion that green tea would counteract most, if not all, compounds that work with boronic acid. However, while there are many chemicals that contain boronic acid, few are being used with patients.

Although the study has exposed detrimental effects of green tea in specific combination with Velcade, this should not minimize the previously reported potentially beneficial effect of this herb, said Dr. Schnthal. Related studies with other types of cancer therapies are promising and green tea extract may actually improve the anticancer effects of other drugs.


'/>"/>

Contact: Patrick C. Irelan
pirelan@hematology.org
202-292-0253
American Society of Hematology
Source:Eurekalert

Related medicine news :

1. USC study finds that green tea blocks benefits of cancer drug
2. Green Tea May Negate the Effects of a Common Cancer Therapy
3. Milkscreen Home Test for Alcohol in Breast Milk Begins Nationwide Sales at Walgreens
4. Recent U.S. Ambassador to Tanzania Mark Green Named Managing Director of Malaria No More Policy Center
5. Healthcare Sector Leaders Urge Obama, Congress to Invest in Alternative Energy and Green Jobs in Healthcare
6. DSM Joins the American Chemical Society Green Chemistry Institute(R)s Pharmaceutical Roundtable
7. Waking Up And Getting Ready: New Green Guide Advocates Simple Living and Earth-Centered Spirituality
8. CMS Data Services Reports Record Response to Data Media "GREEN" Repurchase Program
9. My1Stop.com Partners with Green Business Alliance to Help Customers Go Green
10. Chicago's First Eco-friendly, Green Luxury Dental Practice - ORA Dental Studio - is Finally Here
11. Greenland's National Management of Health Partners with AMD Global Telemedicine Inc. and AFHCAN to Install Telemedicine Encounter Management Systems (TEMS) Across Greenland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... New Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... fitness centers in the U.S., announced today its plans to open a flagship location ... club will occupy the former Rooms To Go store next to Office Depot in ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... been named one of Michigan’s 2017 Best and Brightest in Wellness® by Best ... in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
Breaking Medicine Technology: